Petiq (NASDAQ: PETQ) and Blue Buffalo Pet Products (NASDAQ:BUFF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Petiq and Blue Buffalo Pet Products, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Petiq 0 1 5 0 2.83
Blue Buffalo Pet Products 1 3 7 1 2.67

Petiq presently has a consensus target price of $27.00, suggesting a potential upside of 9.40%. Blue Buffalo Pet Products has a consensus target price of $28.10, suggesting a potential upside of 8.33%. Given Petiq’s stronger consensus rating and higher possible upside, equities analysts clearly believe Petiq is more favorable than Blue Buffalo Pet Products.

Valuation and Earnings

This table compares Petiq and Blue Buffalo Pet Products’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Petiq N/A N/A N/A N/A N/A
Blue Buffalo Pet Products $1.18 billion 4.33 $280.74 million $0.71 36.54

Blue Buffalo Pet Products has higher revenue and earnings than Petiq.

Institutional and Insider Ownership

88.8% of Blue Buffalo Pet Products shares are held by institutional investors. 7.7% of Blue Buffalo Pet Products shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


This table compares Petiq and Blue Buffalo Pet Products’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Petiq N/A N/A N/A
Blue Buffalo Pet Products 12.13% 98.02% 24.56%


Blue Buffalo Pet Products beats Petiq on 8 of the 10 factors compared between the two stocks.

Petiq Company Profile

PetIQ, Inc. is engaged in manufacturing and distributing pet medication and health and wellness products to the retail channel in the United States. The Company provides retail stores with third-party brands, including Frontline Plus, Heartgard Plus, PetAction Plus, Advecta II, Pet Lock Plus, Pet Lock Max, TruProfen and Heartshield. It distributes the products through veterinarian, retail and e-commerce channels. The Company offers its products in a range of categories, including Rx Medications, OTC Medications and Supplies, and Health and Wellness Products. Rx Medications offering includes heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics and other specialty medications. The Company manufactures Heart Shield Plus, version of Heartgard Plus, which prevents heartworm infection in dogs. The Company also manufactures TruProfen, the version of Rimadyl, which treats arthritis in dogs. OTC Medications and Supplies include flea and tick control products.

Blue Buffalo Pet Products Company Profile

Blue Buffalo Pet Products, Inc. (BBPP) is a holding company. The Company operates as a pet food company. The Company, through its subsidiaries, develops, produces, markets and sells pet food under product lines, including BLUE Life Protection Formula, BLUE Wilderness, BLUE Basics, BLUE Freedom and BLUE Natural Veterinary Diet lines. Its product lines of pet food include various product types for dogs and cats. The Company categorizes its products as dry foods, and wet foods, treats and other products. It has a product portfolio across various product types, including diet types, breed sizes for dogs, life stages, flavors, product functions, and textures and cuts for wet foods. BLUE Wilderness is a high-meat, high-protein and grain-free ancestral feeding line. BLUE Basics is a line of limited ingredient diet products for pets with food sensitivities. BLUE Freedom is a grain-free line. BLUE Natural Veterinary Diet is a line of Therapeutic diets for pets, offered through veterinarians.

Receive News & Stock Ratings for Petiq Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petiq Inc and related stocks with our FREE daily email newsletter.